135 related articles for article (PubMed ID: 38722737)
1. Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Fisher OM; Brown C; Esquivel J; Larsen SG; Liauw W; Alzahrani NA; Morris DL; Kepenekian V; Sourrouille I; Dumont F; Tuech JJ; Ceribelli C; Doussot B; Sgarbura O; Alhosni M; Quenet F; Glehen O; Cashin PH;
BJS Open; 2024 May; 8(3):. PubMed ID: 38722737
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
[TBL] [Abstract][Full Text] [Related]
4. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
5. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study.
Prabhu A; Brandl A; Wakama S; Sako S; Ishibashi H; Mizumoto A; Takao N; Ichinose M; Motoi S; Liu Y; Yonemura Y
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839755
[TBL] [Abstract][Full Text] [Related]
6. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
7. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
9. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
[TBL] [Abstract][Full Text] [Related]
12. Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 Apr; 30(4):2486-2493. PubMed ID: 36484904
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
14. Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
Elekonawo FMK; van Eden WJ; van der Plas WY; Ewalds RSG; de Jong LAW; Bremers AJA; Hemmer PHJ; Kok NFM; Kruijff S; Aalbers AGJ; de Reuver PR
BJS Open; 2020 Apr; 4(2):293-300. PubMed ID: 31950702
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
Narasimhan V; Warrier S; Michael M; Ramsay R; Heriot A
J Gastrointest Surg; 2020 Sep; 24(9):2104-2112. PubMed ID: 31745907
[TBL] [Abstract][Full Text] [Related]
17. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
[TBL] [Abstract][Full Text] [Related]
18. Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre.
Hassan S; Dritsas S; O'Dwyer ST; Aziz O; Sutton P; Wang X; Fish R;
Eur J Surg Oncol; 2023 Sep; 49(9):106924. PubMed ID: 37179147
[TBL] [Abstract][Full Text] [Related]
19. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C versus Oxaliplatin after Cytoreductive Surgery for the Treatment of Peritoneal Metastases of Colorectal Cancer Origin.
Papageorgopoulou C; Nikolakopoulos K; Seretis C
Chirurgia (Bucur); 2022 Jun; 117(3):266-277. PubMed ID: 35792537
[No Abstract] [Full Text] [Related]
[Next] [New Search]